Cambridge, Massachusetts, April 27, 2023 /PRNewswire/ — ConcertAI’s TeraRecon’s Eureka Clinical AI platform, including the addition of Combinostics’ cMRI, brings the cutting-edge artificial intelligence and deep learning technologies needed to provide clinicians with comprehensive neuroradiology solutions. provide to clinicians.
MRI brain imaging is an important tool in evaluating patients with neurodegenerative diseases. Visual assessment alone makes it difficult to identify subtle changes in brain atrophy or to identify patterns of atrophy that may be associated with different types of dementia. This can be overcome by using quantitative information. cMRI supports accurate and consistent quantitative assessment of MRI brain scans and presents results in reports designed for physician referral.
Combinostics provides radiology professionals with the AI-powered imaging solutions they need to support unparalleled decision making. cMRI is a fully automated solution that facilitates more accurate and consistent assessment of patients with neurological disorders such as dementia and multiple sclerosis. These AI-based tools will be available on the Eureka Clinical AI platform, giving radiologists access to data-driven decision support and diagnostic enhancement.
“We are excited to make Combinostics’ innovations available within our Eureka Clinical AI platform and to all the valuable clinicians leveraging the TeraRecon solution.” Dan McSweeney, President of TeraRecon. “Adding Combinostics enhances seamless workflow integration and adds efficient and quantitative evaluative image analysis of brain MRI to provide deep, rapid and reliable insights.”
We are pleased to integrate Combinostics’ cNeuro cMRI into TeraRecon’s Eureka Clinical AI platform. Richard Hausmann, CEO, Combinostics. “With this strong collaboration, TeraRecon’s global installed base of approximately 1900 health sites will add our fully automated brain MRI quantification to their comprehensive patient care toolbox, helping to improve dementia and multiple sclerosis. It will be able to support early detection, differential diagnosis, and patient monitoring of neurological diseases such as.
Eureka Clinical AI is the leading AI SaaS image interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. As the industry’s most widely deployed platform, it is unique in that it is open to third-party AI algorithms, with seamless PACS integration for unified management of all AI interpretation solutions. Multidisciplinary care teams can review results and receive mobile alerts to review AI findings to ensure optimal and timely patient intervention, management and coordinated care delivery. increase.
Learn more about the capabilities and algorithms of the Eureka Clinical AI platform spanning neurology, radiology, cardiology, oncology, and more. https://www.terarecon.com/artificial-intelligence
About ConcertAI: ConcertAI is a leader in real-world evidence (RWE) and AI technology solutions for life sciences and healthcare. Our mission is to collaborate with leading biomedical innovators, healthcare providers, and medical societies to accelerate patient insights and outcomes through cutting-edge real-world data, AI technology, and scientific expertise. That’s it. For more information, please visit the following URL: www.concertai.com
About TeraRecon: Serving nearly 1,900 clinical sites worldwide, TeraRecon, a ConcertAI company, is the premier AI-powered KLAS solution provider in radiology, oncology, cardiology, neurology, and vascular surgery . Awarded his KLAS Category Leader for Advanced Visualization, his TeraRecon solution is independent of any manufacturer’s imaging equipment or PACS system and enables a single, integrated and simplified clinical workflow, increasing efficiency. improve and deliver actionable, physician-driven insights. For more information, please visit the following URL: www.terarecon.com
About Combinostics: Combinostics’ AI-powered cNeuro product suite helps clinicians improve the lives of patients with neurological disorders. By quantifying brain imaging and integrating patient data from multiple sources with insights from previous patients, the company’s proprietary software tools empower radiologists and clinicians to confidently make evidence-based diagnoses. and provide the support needed to make management decisions.The company was founded in 2014 and is headquartered in Finland, TampereFor more information, please visit www.combinostics.com.
Media contact: Megan Duero [email protected]
source concert
